Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which citrate solution minimizes metabolic chaos in kidney therapy?

NCT ID NCT07751861

Disease control Sponsor: University Hospital, Antwerp Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests two different concentrations of citrate solution used to prevent blood clotting during continuous kidney replacement therapy in critically ill patients with acute kidney injury. The goal is to see which concentration leads to fewer metabolic complications, such as the need for extra electrolytes like magnesium, phosphate, or potassium. By comparing the low and high concentration solutions, the study aims to identify a safer approach for managing these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low concentrated citrate solution (18 mmol/L) or high concentrated citrate solution (136 mmol/L)
What this could lead to
If one citrate solution proves safer, it could become the standard choice for kidney replacement therapy in intensive care, reducing metabolic complications and improving patient outcomes.
What could go wrong
The trial is relatively small and focuses on a specific ICU population, so results may not apply broadly. Both solutions carry risks of electrolyte imbalances or acid-base disturbances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

176 people

The number who actually took part.

Started

Oct 2023

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any adult patient admitted to the intensive care unit with acute kidney injury requiring continuous kidney replacement therapy Exclusion Criteria: * expected duration of continuous kidney replacement therapy less than 96 hours * prior continuous kidney replacement therapy before inclusion * a known hypersensitivity to citrate, acute liver failure or liver cirrhosis Child-Pugh C * persistent severe hemodynamic shock with decreased lactate clearance * a high likelihood of dying within the first 24h after initiation of CKRT * preexisting severe electrolyte disorders before CKRT initiation not attributable to Acute kidney injury

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury

Contacts and locations

Locations

  • Antwerp University Hospital

    Edegem, Antwerp, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.